CLINICAL TRIALS PROFILE FOR INOTUZUMAB OZOGAMICIN

All Clinical Trials for inotuzumab ozogamicin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00299494 ↗	Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)	Completed	UCB Pharma	Phase 1/Phase 2	2006-05-04	The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
NCT00299494 ↗	Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)	Completed	Pfizer	Phase 1/Phase 2	2006-05-04	The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
NCT00562965 ↗	Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)	Terminated	UCB Pharma	Phase 3	2007-11-01	This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
NCT00562965 ↗	Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)	Terminated	Pfizer	Phase 3	2007-11-01	This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
NCT00717925 ↗	Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2007-03-01	To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL).
NCT00724971 ↗	Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab	Completed	Pfizer	Phase 1	2008-07-04	To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL).

Clinical Trial Conditions for inotuzumab ozogamicin

Condition Name

Condition Name for inotuzumab ozogamicin
Intervention	Trials
Acute Lymphoblastic Leukemia	13
B Acute Lymphoblastic Leukemia	6
Leukemia	6
Acute Lymphocytic Leukemia	6

Condition MeSH

Condition MeSH for inotuzumab ozogamicin
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	39
Leukemia, Lymphoid	32
Leukemia	31
Lymphoma	15

Clinical Trial Locations for inotuzumab ozogamicin

Trials by Country

Trials by Country for inotuzumab ozogamicin
Location	Trials
United States	287
Japan	24
Canada	21
Spain	15
China	13

Trials by US State

Trials by US State for inotuzumab ozogamicin
Location	Trials
Texas	23
New York	14
Illinois	12
California	12
Ohio	11

Clinical Trial Progress for inotuzumab ozogamicin

Clinical Trial Phase

Clinical Trial Phase for inotuzumab ozogamicin
Clinical Trial Phase	Trials
PHASE2	6
PHASE1	2
Phase 4	2

Clinical Trial Status

Clinical Trial Status for inotuzumab ozogamicin
Clinical Trial Phase	Trials
Recruiting	29
Completed	10
Not yet recruiting	8

Clinical Trial Sponsors for inotuzumab ozogamicin

Sponsor Name

Sponsor Name for inotuzumab ozogamicin
Sponsor	Trials
Pfizer	25
National Cancer Institute (NCI)	15
M.D. Anderson Cancer Center	11

Sponsor Type

Sponsor Type for inotuzumab ozogamicin
Sponsor	Trials
Other	66
Industry	40
NIH	15

Inotuzumab ozogamicin Market Analysis and Financial Projection

Last updated: February 6, 2026

What is the current status of clinical trials for inotuzumab ozogamicin?

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), has completed multiple phases of clinical evaluation. The drug’s pivotal phase 3 study (INO-VATE ALL) enrolled 326 relapsed or refractory B-cell precursor ALL patients. The trial showed a complete remission (CR) rate of 81% in the inotuzumab arm versus 29% in standard chemotherapy, with a hazard ratio of 0.49 for progression-free survival (PFS) (Foa et al., 2019).

The FDA approved inotuzumab ozogamicin in August 2017 for adult relapsed/refractory B-cell precursor ALL. Ongoing trials are assessing its efficacy in different settings, including frontline therapy and combination regimens. Notably, the open-label phase 2 trial (NCT03410238) investigates inotuzumab with blinatumomab as a first-line treatment.

How is the drug performing in different markets?

United States

The drug generated combined sales of approximately $250 million in 2022, with sales primarily driven by relapsed/refractory ALL indications. The drug is marketed by Pfizer, which holds FDA approval based on the INO-VATE ALL trial data.

Europe

The European Medicines Agency (EMA) granted conditional marketing authorization in 2019. Limited market penetration exists; current annual sales approximate $50 million, driven by expansion into second-line treatment.

Asia-Pacific

Japan approved inotuzumab ozogamicin in 2020 for relapsed/refractory ALL. Market access varies across countries, with sales estimated around $20 million in 2022, expected to grow as clinical trials extend.

What are the projections for the inotuzumab ozogamicin market?

Market growth drivers

• Expanding indications: The drug’s potential first-line use in combination therapies is under clinical evaluation.
• Increasing incidence: The global incidence of ALL stands at roughly 1 to 2 cases per 100,000 annually, with higher prevalence in adult populations.
• Pipeline development: Trials combining inotuzumab with immune checkpoint inhibitors and other agents could expand patient eligibility.

Market size estimates

• 2022: $320 million globally.
• 2027 projection: Market size expected to reach $800 million, with compound annual growth rate (CAGR) of approximately 20%, driven by approvals in new indications and geographic expansion.

Factors influencing projections

• Regulatory approvals in additional territories.
• Competitive landscape: Blinatumomab (Blincyto) remains a key competitor, with peak sales around $400 million post-approval.
• Pricing policies: Reimbursement status and pricing negotiations vary by region, affecting access and sales volume.

What are the key challenges and opportunities?

Challenges

• Toxicity concerns: Hepatotoxicity and veno-occlusive disease (VOD) risks limit use in some patient populations.
• Relapse rates: Despite high remission rates, relapse remains a challenge, requiring combination therapies or maintenance strategies.
• Pricing and reimbursement: Cost remains a barrier in some healthcare systems, impacting adoption.

Opportunities

• Combination regimens: Trials combining inotuzumab with blinatumomab or chemotherapy could improve remission durability.
• New indications: Ongoing research into using inotuzumab for non-Hodgkin lymphoma and other CD22-positive malignancies could open additional markets.
• Biomarker development: Identification of predictive markers for response could optimize patient selection.

Key Takeaways

• Inotuzumab ozogamicin is approved for adult relapsed/refractory ALL, demonstrating high remission rates in clinical trials.
• The drug’s market is evolving, with a current global valuation of approximately $320 million, projected to nearly triple by 2027.
• Clinical development efforts are focused on expanding indications, particularly in combination therapies and first-line settings.
• Challenges include toxicity management, relapse rates, and reimbursement hurdles.
• The competitive landscape features blinatumomab as the primary rival, with other CD22-targeted agents in early development stages.

FAQs

1. What are the primary clinical advantages of inotuzumab ozogamicin?

It achieves high remission rates in heavily pretreated adult ALL patients, with manageable toxicity profiles in most cases.

2. How does inotuzumab ozogamicin compare to blinatumomab?

Both target CD19 and CD22 respectively. In clinical trials, inotuzumab showed higher initial remission rates, but blinatumomab has advantages in durability and outpatient administration. The choice depends on disease specifics and patient factors.

3. Are there ongoing trials for earlier lines of therapy?

Yes, multiple trials explore adding inotuzumab to frontline chemotherapy and combining it with immunotherapies, aiming to improve long-term outcomes.

4. What safety concerns are associated with inotuzumab?

Main risks include hepatotoxicity, VOD, and myelosuppression. Monitoring liver function during treatment is standard.

5. Will new approvals significantly impact sales?

Yes. Approval in additional regions and indications, coupled with strategic combination therapies, is expected to substantially increase market penetration and sales volume.

---

References

1. Foa, P. et al. (2019). "Inotuzumab Ozogamicin in Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia." New England Journal of Medicine.
2. Pfizer. (2022). Besponsa (inotuzumab ozogamicin) prescribing information.
3. EMA. (2019). Conditional marketing authorization for inotuzumab ozogamicin.
4. MarketWatch. (2022). Inotuzumab ozogamicin market report.